Compare VVX & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVX | AGIO |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2014 | 2013 |
| Metric | VVX | AGIO |
|---|---|---|
| Price | $75.57 | $26.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $69.88 | $38.88 |
| AVG Volume (30 Days) | 379.6K | ★ 1.3M |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 126.85 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $4,480,038,000.00 | $43,011,000.00 |
| Revenue This Year | $7.81 | $76.75 |
| Revenue Next Year | $5.84 | $170.73 |
| P/E Ratio | $126.13 | ★ N/A |
| Revenue Growth | ★ 3.65 | N/A |
| 52 Week Low | $43.42 | $22.24 |
| 52 Week High | $78.36 | $46.00 |
| Indicator | VVX | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 69.40 | 41.48 |
| Support Level | $66.12 | $26.03 |
| Resistance Level | N/A | $29.58 |
| Average True Range (ATR) | 2.74 | 1.36 |
| MACD | 1.14 | -0.16 |
| Stochastic Oscillator | 83.97 | 21.85 |
V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.